Novel Laboratories Recalls Zolpidem Tartrate Blister Packs Due to Failure to Meet Child-Resistant Closure Requirement; Risk of Poisoning

What was recalled

In the landscape of prescription medications, precision in packaging is just as critical as the chemical composition of the pill itself. On July 27, 2016, the U.S. Consumer Product Safety Commission (CPSC) announced a significant recall initiated by Novel Laboratories, a pharmaceutical manufacturer based in New York. This action was taken regarding specific batches of Zolpidem Tartrate sublingual tablets, a prescription sleep aid designed to help individuals with insomnia fall asleep quickly. The core issue driving this recall was not the medication itself, but rather the way it was packaged for consumer safety.

The affected products are specifically the 1.75 mg and 3.5 mg strengths of Zolpidem Tartrate sublingual (rapid dissolve) tablets. These medications come in a distinctive single-tablet blister pack format, which is designed to be peeled open and pushed through for rapid dissolution under the tongue. Each individual blister pack is housed within an outer open-ended pouch, with boxes containing 30 of these pouches. The packaging is visually identifiable by the brand name "Gavis" printed in blue on the center of both the white boxes and the pouches. It is crucial for patients to check their specific inventory against the detailed identifiers provided below, as only certain lots were affected.

To determine if a specific box is part of this recall, consumers must look for very precise lot numbers and National Drug Codes (NDC). The recall applies exclusively to the 1.75 mg tablets with lot number M16140A and NDC 43386-762-30. For the higher dosage, the recall covers the 3.5 mg tablets with lot number M16144A and NDC 43386-761-30. On the packaging itself, the lot number and an expiration date of February 2018 are printed on the bottom left corner of the pouches, while the NDC is located on the top left corner of the outer box. Novel Laboratories did not report any specific incidents or injuries at the time of the recall, but the potential for harm was significant enough to warrant immediate action.

This recall highlights the importance of regulatory compliance in pharmaceutical distribution. The Poison Prevention Packaging Act requires that certain dangerous substances, including prescription sleep aids, be packaged in child-resistant containers to prevent accidental ingestion by young children. Novel Laboratories determined that the blister packs used for these specific lots failed to meet this mandatory child-resistant closure requirement. While the medication is effective for its intended purpose, the packaging failure created a scenario where a curious child could potentially access the tablets without difficulty, leading to a serious risk of poisoning. Consumers who possess these specific items were urged to immediately stop using them and contact Novel Laboratories for instructions on how to return the product and receive a full refund.

The hazard, explained

To understand why this recall is taken so seriously, we need to look at the specific physical failure that triggered it. The core issue here is not with the medication itself—Zolpidem Tartrate remains a potent and effective sleep aid—but with the container holding it. Under federal law, specifically the Poison Prevention Packaging Act, prescription drugs that can be harmful if ingested by young children must be packaged in special child-resistant containers. These are designed to require a level of dexterity, strength, and coordination that most children under five years old do not yet possess. The packaging for these specific 1.75 mg and 3.5 mg sublingual tablets from Novel Laboratories failed to meet that standard. Instead of a secure, locking bottle or a complex blister pack, the drug was sealed in a simple peel-and-push blister inside an open-ended pouch. This type of packaging is generally considered easy for small fingers to manipulate, effectively bypassing the safety barrier intended to protect them.

The danger becomes clear when we consider how Zolpidem works in the body. As a prescription sleep medication, it is a central nervous system depressant. Its job is to slow down brain activity to induce sleep. For an adult taking the correct dose under medical supervision, this effect is controlled and manageable. However, for a small child, even a single tablet can be disproportionately dangerous. Children have much lower body weights than adults, meaning their bodies process drugs differently and more intensely. If a child manages to peel open that blister pack—which the recall indicates they easily can—they may swallow the entire 1.75 mg or 3.5 mg dose. This is not a trivial amount for a toddler or preschooler.

When ingested by a young child, this medication can lead to serious poisoning. The physical mechanism of harm involves the drug rapidly entering the bloodstream and suppressing vital bodily functions. Symptoms of Zolpidem poisoning in children can include extreme drowsiness, confusion, slowed breathing, and in severe cases, coma or death. Because the tablets are designed to dissolve rapidly under the tongue (sublingual), they begin acting quickly once swallowed. The open-ended pouch offers no secondary barrier; if the blister is breached, the pill is exposed and accessible. There have been no reported incidents of poisoning from this specific batch to date, which is fortunate, but the risk remains real because the packaging does not prevent access. It relies on a level of child-proofing that simply does not exist in a standard peel-and-push format, leaving children vulnerable to accidental ingestion of a drug they were never meant to touch.

Who is most at risk

When we talk about product recalls involving prescription medications, it is easy to focus solely on the chemical properties of the drug itself. However, the specific hazard in this recall from Novel Laboratories is structural rather than pharmacological. The issue lies entirely with the packaging: the blister packs fail to meet the federal child-resistant closure requirements mandated by the Poison Prevention Packaging Act. Because the risk is defined by the inability of a child to be prevented from accessing the medication, the primary group at immediate and severe risk is children under the age of five. This demographic is uniquely vulnerable not because they are more sensitive to zolpidem than adults, but because their behavior and physical capabilities align perfectly with the failure mode of this specific packaging.

Young children are naturally curious explorers who often put objects in their mouths as a way to understand the world. The recalled product is packaged in single-tablet peel-and-push blister packs housed within open-ended pouches. While these materials might seem secure to an adult hand, they do not require the specific dexterity, strength, or coordinated effort that child-resistant containers are engineered to demand. A toddler can often tear open a soft pouch or pop out a tablet from a standard blister pack with surprising ease. Once a child ingests even a small amount of zolpidem tartrate, the consequences can be catastrophic. Zolpidem is a central nervous system depressant used to treat insomnia; in a small body, it can cause profound sedation, slowed breathing, coma, and potentially death. The fact that there have been no reported incidents as of the recall date is fortunate, but it does not negate the high potential for tragedy given the accessibility of the product.

While children are the primary concern driving this regulatory action, other household members may also face indirect risks. For instance, elderly individuals or those with cognitive impairments who may have difficulty opening standard child-resistant caps might find these easier-to-open packages convenient. However, this convenience comes with a hidden danger: if such a package is accessible to children in the home, the ease of opening becomes a liability rather than an aid. Additionally, anyone living in a multigenerational household where young children visit frequently or live with older adults who take sleep aids must be vigilant. The drug itself is not dangerous if swallowed accidentally by an adult in a therapeutic context, but the packaging flaw creates a universal hazard for any unauthorized access. Therefore, the risk extends to any situation where this medication is stored within reach of a child, regardless of who the primary user is. It is crucial to remember that "child-resistant" is a legal standard meant to delay or prevent access by young children, not just make it difficult. When that standard is not met, the barrier against accidental poisoning disappears entirely.

How to tell if you have the recalled item

When dealing with a medication recall, particularly one involving prescription sleep aids like Zolpidem Tartrate manufactured by Novel Laboratories, precise identification is critical because the issue lies in the packaging rather than the chemical composition of the drug itself. To determine whether your specific supply is part of this recall, you must carefully inspect both the individual blister packs and the outer shipping box. Do not rely solely on the expiration date or the brand name "Gavis" alone, as these features are present on both recalled and non-recalled items. Instead, you need to verify three specific data points: the dosage strength, the National Drug Code (NDC), and the lot number.

First, check the strength of the tablets. This recall applies exclusively to two specific dosages of sublingual (rapid dissolve) Zolpidem Tartrate: 1.75 mg and 3.5 mg. If you have a different strength, such as 5 mg or 10 mg, this specific recall does not apply to your medication. Next, look at the outer white box. You should see the word "Gavis" printed in blue on the center of the box. On the top left corner of this box, locate the National Drug Code (NDC). For a potential match, the NDC must be exactly 43386-761-30 for the 3.5 mg tablets or 43386-762-30 for the 1.75 mg tablets.

The most definitive way to confirm if your item is part of this recall is by examining the individual blister pack inside the box. Each package contains a single tablet in a peel-and-push blister pack, which is housed within an outer open-ended pouch. Look at the bottom left corner of this pouch. Here, you will find the lot number printed alongside an expiration date of 02/2018. For the 3.5 mg tablets, the lot number must be M16144A. For the 1.75 mg tablets, the lot number must be M16140A. If your pouch displays either of these lot numbers combined with the corresponding NDC listed above, your medication is part of this recall. Remember that the packaging failure involves a lack of child-resistant closure, so even if the pills look normal, the safety mechanism intended to prevent accidental ingestion by children is missing.

• Dosage: 1.75 mg or 3.5 mg Zolpidem Tartrate sublingual tablets.
• Brand Name: Gavis (printed in blue on the white box and pouch).
• Outer Box NDC (Top Left Corner): 43386-761-30 (for 3.5 mg) or 43386-762-30 (for 1.75 mg).
• Pouch Lot Number (Bottom Left Corner): M16144A (for 3.5 mg) or M16140A (for 1.75 mg).
• Expiration Date: 02/2018.

If you cannot find these specific lot numbers or NDCs, your medication is likely not affected by this particular recall. However, if you are unsure or if the labels are faded, it is safer to treat the item as potentially recalled and contact Novel Laboratories for verification before disposing of or using the medication.

What to do — step by step

Your refund, repair, or replacement options

If you have identified that you possess one of the recalled Zolpidem Tartrate blister packs from Novel Laboratories, your immediate and most straightforward option is to seek a full refund for the product. It is important to understand that this recall does not offer a repair service, nor does it provide a direct replacement with a new, compliant package. The hazard here is intrinsic to the packaging design itself—specifically, the failure of the blister pack to meet child-resistant closure requirements mandated by the Poison Prevention Packaging Act. Because the safety issue lies in how the medication is contained rather than in the medication’s efficacy or manufacturing defect, simply swapping the box for another identical one would not resolve the problem. Therefore, the Consumer Product Safety Commission (CPSC) and Novel Laboratories have established a remedy focused entirely on removing the non-compliant product from your home and returning your money.

To initiate this process, you must contact Novel Laboratories directly. The company has set up a dedicated toll-free line for consumers affected by this recall: (866) 403-7592. You can reach them by phone between the hours of 9 a.m. and 5 p.m. Eastern Time, Monday through Friday. When you call, be prepared to provide specific details about your product to verify that it is part of this recall. Have your box and blister packs ready so you can read aloud the lot numbers and National Drug Codes (NDCs) found on the packaging. For the 1.75 mg tablets, look for lot number M16140A and NDC 43386-762-30. For the 3.5 mg tablets, check for lot number M16144A and NDC 43386-761-30. Providing these exact identifiers will help the representative confirm your eligibility for a refund quickly and accurately.

If you prefer not to call or if you encounter difficulties with the phone line, Novel Laboratories also offers an online resource for more information. You can visit their website at www.novellabs.net. Once on the site, navigate to the section labeled "Important Zolpidem Information." This page is dedicated to addressing the concerns related to this specific recall and should provide further instructions or digital forms if necessary. It serves as a valuable backup resource if you need to verify details or find additional guidance beyond what is provided over the phone.

While waiting for your refund, do not attempt to reuse the packaging for any other purpose, nor should you try to transfer the tablets into a different container yourself unless explicitly instructed by customer service. The goal is to ensure that these specific packages are handled safely until they are retrieved or destroyed. Remember, the remedy provided is a full refund, meaning you should not incur any costs associated with returning the product if such instructions are given, though the recall facts do not specify shipping procedures, so clarifying this during your contact with Novel Laboratories is advisable. This process is designed to be simple and stress-free, allowing you to secure your funds while eliminating the risk of accidental poisoning to children in your household.

What can happen if you ignore it

It is completely understandable to feel hesitant about discarding medication, especially when you are relying on it for rest and recovery. You might look at the blister packs sitting on your nightstand and think that since they have worked in the past, there is no urgent need to act. However, ignoring this recall is not merely an administrative oversight; it is a direct gamble with safety, particularly for households where children or vulnerable individuals have access to the medication. The core issue here is not the drug itself, which is a legitimate treatment for sleep disorders, but the failure of its container to provide the necessary barrier against accidental ingestion.

The Poison Prevention Packaging Act exists because prescription medications can be deadly even in small doses when consumed by those who are not prescribed them. Zolpidem Tartrate is a central nervous system depressant designed to induce sleep. For an adult taking the correct dose under medical supervision, it is effective and generally safe. But for a child, or someone who has not been evaluated for drug interactions, even a single tablet from these specific blister packs can lead to severe poisoning. Symptoms of zolpidem poisoning in children can include extreme drowsiness, confusion, slowed breathing, loss of coordination, and in serious cases, coma or respiratory failure. The lack of a child-resistant closure means that a curious toddler could potentially pull the foil back with ease, or an elderly person with limited dexterity might accidentally drop pills into their hand while trying to open the pouch.

You might wonder if the risk is minimal because you are careful. While your vigilance is commendable, accidents often happen in split seconds—when a caregiver is distracted, when a child finds a discarded box in the trash, or when multiple people share a living space. The recall data indicates that no incidents have been reported to date, which is fortunate but does not guarantee safety for your specific home environment. Relying on the absence of past reports is a logical fallacy; it only takes one moment of carelessness for a tragedy to occur. By continuing to use these non-compliant packages, you are removing the last line of defense that the law intended to provide.

Furthermore, ignoring the recall denies you the opportunity to secure a safe alternative. If you continue to use the recalled stock, you are not just risking accidental poisoning; you are also potentially dealing with the stress and medical costs associated with an emergency response later. The remedy offered by Novel Laboratories is straightforward: stop using the product and return it for a full refund. This process eliminates the hazard entirely. There is no need to fear that your sleep issues will go untreated; you can simply work with your healthcare provider to obtain new prescriptions packaged in compliant, child-resistant containers. Choosing to keep the recalled items prioritizes convenience over the irreplaceable safety of your loved ones.

Staying safe: broader tips

When it comes to prescription medications, particularly those that affect the central nervous system like Zolpidem Tartrate, safety extends far beyond a single product recall. While manufacturers are legally required to use child-resistant packaging under the Poison Prevention Packaging Act, no container is truly "child-proof." A determined toddler or curious young child can often open standard blister packs or pouches with surprising ease. Therefore, relying solely on the packaging’s design is not enough. The most effective defense is active management of where and how these medications are stored. Always keep prescription drugs in their original containers with the child-resistant caps tightly secured after every use. If you have transferred pills to a daily organizer, be aware that standard pill boxes offer zero protection against ingestion by small children and should never be left within reach or sight of anyone under five years old.

Storage location is equally critical. A common mistake is placing medication in high cabinets that are technically out of reach but easily accessible via a step stool or chair. Instead, opt for locked cabinets or drawers that are completely out of the child’s line of sight and physical access. It is also wise to use locks with keys rather than complex dials, as young children can sometimes learn to manipulate simple locking mechanisms if they observe an adult doing so repeatedly. Never refer to medicine as "candy" when telling a child to take it, as this can inadvertently create a positive association with the pills in their minds.

For households with very young children or individuals who may be vulnerable to accidental ingestion, consider using safety boxes designed specifically for medications. These are heavy, lockable containers that require a combination or key to open, providing a robust layer of security that goes beyond standard cabinet locks. Additionally, educate all caregivers—whether grandparents, babysitters, or family friends—on the specific risks and storage protocols for every medication in the home. Accidents often happen when someone unfamiliar with the household’s safety routines handles the pills.

Finally, stay proactive about general product safety by regularly checking official recall databases like those maintained by the Consumer Product Safety Commission (CPSC) or the Food and Drug Administration (FDA). Subscribing to email alerts from these agencies can provide early warnings about defects or hazards in everyday items, from cribs to electronics. Knowing how to identify lot numbers and expiration dates on products, as highlighted in this recall, empowers you to quickly verify if an item in your home is part of a safety notice. Being informed is the best way to prevent tragedy before it happens.

• Always keep medications in their original, labeled containers with child-resistant caps securely fastened.
• Store prescription drugs in locked cabinets or high places that are completely out of sight and reach.
• Educate all caregivers about proper medication storage and the specific dangers of each drug in the household.
• Subscribe to safety alerts from government agencies to stay informed about recalls on various products.